Palatin Technologies (NYSEAMERICAN:PTN) Stock Falls 7.8% – Time to Sell?

Palatin Technologies (NYSEAMERICAN:PTN) traded down 7.8% during trading on Tuesday. The stock traded as low as $5.40 and last traded at $5.52. Approximately 64,641 shares changed hands during mid-day trading, an increase of 84% from the average daily volume of 35,075 shares. The stock had previously closed at $5.99.

Palatin Technologies Trading Down 0.7%

The firm has a fifty day moving average price of $9.81 and a 200 day moving average price of $12.32.

Palatin Technologies (NYSEAMERICAN:PTN) last announced its quarterly earnings data on Monday, September 28th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.09. The firm had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $1.50 million.

Institutional Trading of Palatin Technologies

An institutional investor recently bought a new stake in Palatin Technologies stock. Opaleye Management Inc. purchased a new position in shares of Palatin Technologies (NYSEAMERICAN:PTN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 20,500 shares of the company’s stock, valued at approximately $221,000. Opaleye Management Inc. owned about 1.15% of Palatin Technologies at the end of the most recent reporting period. Institutional investors own 11.50% of the company’s stock.

Palatin Technologies Company Profile

Palatin Technologies, Inc is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, a group of receptors involved in regulating sexual function, inflammation, metabolism and other physiological processes. The company’s research programs are designed to use these pathways to address conditions with limited treatment options.

Palatin’s best-known product is Vyleesi (bremelanotide), an injectable melanocortin-4 receptor agonist approved by the U.S.